Skip to main content
Premium Trial:

Request an Annual Quote

Third Wave Shares Nosedive Even Though Firm Beat Q3 Revenue Expectations

NEW YORK, Oct. 27 (GenomeWeb News) - Shares in Third Wave Technologies were down 16.3 percent in early-afternoon trading as investors slammed the company despite beating top-line projections for the third quarter.


Third Wave's stock was trading down $1.30 at $6.70 on the Nasdaq exchange after nosediving to $5.97 in 30 minutes of heavy trading after the market opened.


Wall Street was unimpressed with the company's $1.1 million year-over-year revenue growth, which increased to $10.5 million, despite beating market expectations. Third Wave also raised its year-end revenue projections, saying it expects to post $43 million in receipts by the end of the year.


The company, which also said it plans to replace CFO David Nuti by the end of the month, spent $2.7 million on R&D expenses for the quarter, compared with $2.8 million last year.


Adam Chazan, who covers Third Wave for Pacific Growth Equities, attributed the stock tumble to the CFO change, as well as to other management changes the company announced today. He also said investors may have been spooked by Third Wave's 2004 revenue guidance, which he called "conservative."


Third Wave's net income totaled $24,000, representing no earnings per share, compared to a net loss of $1.4 million, or $.04 per diluted share, for the same period last year.


As of Sept. 30, Third Wave had $67.1 million in cash, cash equivalents, and short-term investments.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.